BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWayâs flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications. BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY. Source
No articles found.
Amedisys, Inc. is a leading healthcare at home Company delivering personalized hom...
Amedisys, Inc. is a leading healthcare at home ...
Entera Bio is a clinical-stage biopharmaceutical company focused on the developmen...
Entera Bio is a clinical-stage biopharmaceutica...
Mylan is a global pharmaceutical company committed to setting new standards in hea...
Mylan is a global pharmaceutical company commit...
Bionano is a life sciences instrumentation company in the genome analysis space. B...
Bionano is a life sciences instrumentation comp...
We enable cheaper, faster, and better genetic engineering of plants. We offer our ...
We enable cheaper, faster, and better genetic e...
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into ...
Sangamo Therapeutics, Inc. is focused on transl...
Viveve, Inc., the wholly owned subsidiary of Viveve Medical, Inc., is a women's in...
Viveve, Inc., the wholly owned subsidiary of Vi...
Join the National Investor Network and get the latest information with your interests in mind.